January 03, 2025

To,
National Stock Exchange of India Limited
Listing & Compliance Department
Exchange Plaza, 5th Floor, Plot No. C/1,
G Block, Bandra-Kurla Complex, Bandra
Mumbai, 400051, Maharashtra, India.

Company Symbol : **MEDIORG**
Company ISIN : **INE0PE401018**

Dear Sir/Madam,

Subject: Press Release - Medicamen Organics Completes Incorporation of Subsidiary to Expand Presence in Healthcare Industry in Key Markets

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a copy of the Press Release titled - **"Medicamen Organics Completes Incorporation of Subsidiary to Expand Presence in Healthcare Industry in Key Markets".**

A copy of the same will also be uploaded on the Company's website www.medicamenorganics.com.

Kindly take the same on record and display the same on the website of your exchange.

Thanking you.

Yours faithfully,

For and on behalf of
Medicamen Organics Limited

Ashutosh Gupta
Digitally signed by Ashutosh Gupta
DN: cn=Ashutosh Gupta, o, ou, email=jan@gmail.com, c=IN
Date: 2025.01.03 16:04:45 +05'30'

Ashutosh Gupta
Whole-time Director
DIN: 00039995

Place: New Delhi

Encl.: as stated above

Medicamen Organics Completes Incorporation of Subsidiary to Expand Presence In Healthcare Industry In Key Markets

New Delhi, January 03, 2025 – Medicamen Organics Limited (MOL) (NSE- MEDIORG) one of the leading manufacturers of pharmaceuticals and health products, is pleased to announce the incorporation of a new subsidiary, Grande Etoile Pharmaceuticals Limited (GEPL).

GEPL, established as a public limited company in India, has an initial authorised capital of ₹ 1 Cr and paid-up share capital of ₹50 Lakh. The shareholding structure consists of 50.92% ownership by Medicamen Organics Limited and 49.08% by other shareholders. Also, the company acquired 2,54,600 equity shares at par, with a face value of ₹10 each.

The primary objective of GEPL is to strengthen the company's footprint in the Pharmaceuticals, Healthcare, and Cosmetics industry. The acquisition aligns seamlessly with the company's strategic goals. The subsidiary will focus on distribution and exports of pharmaceutical products, including medicines, antibiotics, vaccines, and dietary supplements, as well as cosmetics and personal care items. This initiative is part of the company's broader strategy to diversify its portfolio, enhance its distribution network, and explore new market opportunities in the evolving healthcare and wellness industry.

Medicamen Organics Limited is committed to fortifying its presence internationally through strategic acquisitions aimed at building a strong footprint in the pharmaceutical sector. This initiative is poised to serve as a catalyst for sustained business growth in the years to come.

Commenting on the Subsidiary, Mr. Bal Kishan Gupta, Managing Director said, " This is a pivotal step in enhancing company's standing as a leader in the healthcare and pharmaceuticals industry. The establishment of Grande Etoile Pharmaceuticals Limited not only reinforces our commitment to innovation but also enables us to address the rapidly growing demand for quality healthcare products across diverse markets. By broadening our portfolio and increasing our operational scope, we are positioning the Company to unlock new growth opportunities, brand promotion and faster penetration in key markets.

We believe this move will not only contribute to financial performance but also enable us to play a more meaningful role in improving access to affordable and reliable healthcare solutions globally."

About Grande Etoile Pharmaceuticals Limited (GEPL):

Grande Etoile Pharmaceuticals Limited (GEPL) is a newly incorporated subsidiary of Medicamen Organics Limited, focused on the Pharmaceuticals, Healthcare, and Cosmetics industries. GEPL aims to export a diverse range of products including medicines, antibiotics, vaccines, dietary supplements, and personal care items. Additionally, the company will engage in the distribution, and export of these products. GEPL's establishment marks a key milestone in expanding Medicamen Organics' portfolio and reinforcing its position within the evolving healthcare and wellness sector globally.

About Medicamen Organics Limited

Medicamen Organics Limited stands out as a prominent player in the pharmaceutical sector, specializing in the development, manufacturing, and distribution of an extensive range of pharmaceutical dosage forms. These include Tablets, Capsules, Oral Liquids, Ointments, Gels, Syrups, Suspensions, and Dry Powders. The company's diverse offerings serve both state and central government institutions as well as private entities, operating as a contract and third-party manufacturer

The company has two WHO GMP-approved manufacturing facilities located in Haridwar, Uttarakhand, covering an area of 21,536 sq. ft. These facilities feature cutting-edge infrastructure and in-house testing laboratories. A team of skilled and experienced professionals supports a streamlined production process, maintaining consistent quality.

Focused on global expansion, the company's products are distributed not only throughout India but also in African, CIS, and Southeast Asian countries, including Congo, Benin, Cameg, Togo, Senegal, Burkina Faso, the Philippines, Myanmar, Mozambique, Kyrgyzstan, and Kenya.

The company's core business model revolves around B2B contract manufacturing, partnering with third-party pharmaceutical companies to market and sell its products. Medicamen Organics also engages actively in government tenders, supplying products to government hospitals, departments, PSUs, and armed forces.

The Company got listed on NSE Emerge in June 28, 2024.

For FY24, the Company has reported Total Income of ₹ 25.29 Cr, with EBITDA of ₹ 4.76 Cr & PAT of ₹ 2.62 Cr.

Disclaimer

For Further Information Please Contact Corporate Communication Advisor

Kirin Advisors	**Kirin Advisors Private Limited** Sunil Mudgal – Director sunil@kirinadvisors.com +91 98692 75849 www.kirinadvisors.com